Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1998-01-27
2000-07-18
Eisenschenk, Frank C.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
435326, 4352523, 4353201, C12N 1513, C12N 120, C07H 2104
Patent
active
060909307
ABSTRACT:
The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.
Carr Francis
Garin-Chesa Pilar
Old Lloyd J.
Rettig Wolfgang J.
Wallace Thomas Paul
Eisenschenk Frank C.
Ludwig Institute for Cancer Research
LandOfFree
Recombinant human anti-FB5 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant human anti-FB5 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant human anti-FB5 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2038132